← All trials
NCT06561308
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2024
- Primary completion
- Sep 1, 2029
- Completion date
- Dec 1, 2029
- First posted
- Aug 20, 2024
- Last posted
- Aug 20, 2024
- Enrollment
- 39
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Zhejiang UniversityLead sponsor
- Zhengzhou UniversityCollaborator
- Chinese Academy of Medical SciencesCollaborator
- Ningbo No. 1 HospitalCollaborator
- Central South UniversityCollaborator
- Central South UniversityCollaborator
- Wenzhou Medical UniversityCollaborator
- Henan Provincal People's HospitalCollaborator
- Zhejiang UniversityOfficial
- Shandong UniversityCollaborator
- Anhui Medical UniversityCollaborator
- University of Electronic Science and Technology of ChinaCollaborator
- Huazhong University of Science and TechnologyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.